NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Stock Information for NeuroOne Medical Technologies Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroOne Medical Technologies Corporation

NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne® Issues Letter to Shareholders
NeuroOne® OneRF® Technology Success Story Featured on Fox News
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.